A Phase II Study of Cryoablation Combined with Anti-PD-1 Antibody (SHR-1210) in Patients with Advanced Intrahepatic Cholangiocarcinoma
Latest Information Update: 05 Mar 2025
At a glance
- Drugs Camrelizumab (Primary)
- Indications Cholangiocarcinoma; Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 27 Feb 2025 Planned End Date changed from 10 May 2024 to 30 Dec 2026.
- 27 Feb 2025 Planned primary completion date changed from 10 May 2024 to 30 Dec 2025.
- 12 Sep 2023 Planned End Date changed from 10 May 2023 to 10 May 2024.